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ventive	 intravenous	 administration	 of	 the	 deficient	 coagu旭ation	
factorp	 a	 treatment	 strategy	 ca旭旭ed	 prophy旭axiss2	 The	 dose	 and	
frequency	 of	 factor	 concentrate	 infusions	 to	 improve	 important	
patient	outcomesp	such	as	a	reduction	in	the	number	and	severity	





the	processp	 iep	 the	mechanisms	 旭inking	 the	p旭asma	activity	 旭eve旭	
of	 c旭otting	 factor	 concentrate	with	 the	 re旭evant	outcomes	Other	




factor	 concentratesp	 targeted	 or	 to旭erated	 annua旭ized	 b旭eeding	





























K E Y W O R D S
factor	IXp	factor	VIIIp	popu旭ation	pharmacokineticsp	tai旭ored	prophy旭axisp	tai旭oring
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within	an	individua旭	over	time	or	across	different	concentrates	of	




patient	 needsp	 tai旭oring	 treatment	 to	 individua旭	 characteristicsp	







ゴ科 |科MANUSCRIPT DEVELOPMENT  
WORKFLOW
This	 manuscript	 is	 the	 resu旭t	 of	 the	 co旭旭aborative	 effort	 of	 the	
working	 party	 on	 Popu旭ation	 Pharmacokinetics	 of	 the	 Scientific	
Standardization	 Committee	 ｪSSCｫ	 of	 the	 Internationa旭	 Society	 for	




These	 recommendations	 can	 be	 found	 in	 Iorio	 et	a旭sゾ	 The	 present	
documentp	a旭though	not	an	officia旭	communication	of	the	SSCp	e旭ab､
orates	 on	 pharmacokinetics	 in	 hemophi旭ia	 beyond	 what	 cou旭d	 be	
addressed	in	Iorio	et	a旭sゾ	Open	comments	from	experts	in	the	fie旭d	
of	 coagu旭ation	 factor	 concentrates	 PK	 ｪindependent	 investigatorsp	
pharmaceutica旭	 company	 PK	 expertsp	 and	 members	 of	 regu旭atory	
bodiesｫ	were	invited	beyond	the	origina旭	Working	Party	memberships
ザ科|科THE EMPIRICAL APPROACH TO DOSING 





standard	 ha旭f､	旭ife	 factor	 VIII	 concentrate	 as	 an	 examp旭ep	 a	 typica旭	
dosing	regimen	wou旭d	be	ゴグ	to	ジグ	IU｠kg	administered	every	other	
days	Assuming	a	recovery	of	グsグゴ	IU｠mL	ｪies	ゴ	IU｠dLｫ	for	each	ゲ	IU｠






When	 旭ooking	 across	 c旭asses	 of	 concentratesp	 the	 way	 that	
concentrate､	specific	PK	properties	are	accounted	for	 is	 in	the	rec､
ommended	starting	regimens	for	the	phase	III	studiess	For	examp旭ep	
ズグ	IU｠kg	 twice	 a	 week	 or	 ゲググ	IU｠kg	 week旭y	 for	 a	 standard	 ha旭f､	






Furthermorep	 this	 wpopu旭ation	 averagex	 approach	 does	 not	 ac､





ジ科 |科ESTABLISHED USES OF PK 
MEASURES IN ROUTINE CLINICAL 
CARE OF PERSONS WITH 










the	p旭asma	activity	 旭eve旭	of	 the	 infused	 factor	 is	 sti旭旭	 above	 the	 旭eve旭	
considered	critica旭	to	prevent	b旭eedings13	This	critica旭	thresho旭d	is	often	




To	 ensure	 b旭eeding	 contro旭	 during	 surgeryp	 nationa旭	 and	 inter､
nationa旭	 guide旭ines	 recommend	 maintaining	 p旭asma	 activity	 旭eve旭s	
of	 factor	concentrates	above	specific	 thresho旭ds	 for	specific	dura､
tions	 of	 timep	 both	 of	which	 depend	 on	 the	 type	 of	 surgerys14	 As	












ongoing	 to	 eva旭uate	 this	 approach	 to	 individua旭ized	 dosing	 in	 the	
perisurgica旭	settings18
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Defining	 to旭erance	 in	 the	 context	 of	 an	 ITI	 regimen	 after	 the	
inhibitor	 is	 no	 旭onger	 detectab旭e	 with	 the	 Bethesda	 assay	 ｪidea旭旭y	





Doctorsv	Organisation	 ｪUKHCDOｫ	 that	 uses	 on旭y	 trough	 旭eve旭	 and	
mitigates	the	need	to	take	mu旭tip旭e	samp旭es	to	assess	both	recovery	
and	ha旭f､	旭ifes23	Ca旭cu旭ating	the	ha旭f､	旭ife	or	measuring	the	recovery	or	
trough	 旭eve旭	of	 the	 infused	 factor	constitutes	a	 ｪsimp旭ifiedｫ	PK	ap､
proach	to	tai旭oring	individua旭	treatments
ズ科 |科THE IMPORTANCE OF RELIABLE 
LABORATORY MEASUREMENTS
An	important	consideration	when	using	p旭asma	factor	activity	旭eve旭	
measurements	 for	 c旭inica旭	 purposes	 is	 the	 precision	 and	 accuracy	
of	the	旭aboratory	measurementss	There	is	robust	evidence	that	the	
choice	of	assay	type	ｪiep	one､	stage	versus	chromogenicｫp	the	choice	







ica旭	 coefficient	of	variation	of	measurements	 for	c旭otting	assays	 is	
equa旭	to	or	be旭ow	ゲズ鯵	that	resu旭ts	inp	for	examp旭ep	a	measurement	
of	 グsズグ	IU｠mLp	 if	 repeated	 mu旭tip旭e	 timesp	 giving	 resu旭ts	 between	
グsジザ	IU｠mL	to	グsズゼ	IU｠mL	two､	thirds	of	the	times
The	systematic	error	 trans旭ates	 into	poor	accuracy	or	 signifi､
cant	deviation	from	the	true	va旭ues	For	examp旭ep	a	test	based	on	
a	specific	reagent	wi旭旭	systematica旭旭y	report	a	旭ower	or	higher	re､






specific	 standardsゴゼpゴ芦	 This	 a旭so	 seems	 to	 be	 re旭evant	 for	 some	
wi旭d	type	and	modified	recombinant	and	p旭asma､	derived	FVIII	and	
FIX	productspゴゾ･ザゲ	specifica旭旭y	where	the	one､	stage	c旭otting	assay	
resu旭t	 is	 inf旭uenced	by	 the	aPTT	 reagent	 se旭ecteds32	A	 review	of	
the	current	evidence	about	the	performance	of	different	reagents	
for	 different	 factor	 concentrates	 has	 been	 performed	 by	 Young	
and	co旭旭eaguess33	Manufacturers	are	responsib旭e	for	providing	in､
formation	to	c旭inica旭	 旭aboratories	on	appropriate	assay	and	assay	















葦科 |科DOSE INDIVIDUALIZATION BASED ON 










葦sゲ科|科Traditiona旭 approach to obtaining individua旭 PK 
information and its disadvantages
A旭旭	non､	empirica旭	ｪiep	non･xtria旭	and	errorxｫ	approaches	to	ca旭cu旭ate	















葦sゴ科|科PopPK approach and Bayesian estimation to 
obtaining individual PK information
Determination	 of	 individua旭	 PK	 parameters	 can	 be	 achieved	 with	
fewer	 samp旭es	 than	 the	 traditiona旭	 approach	 through	 integration	
of	 information	 from	 both	 a	 patient	 popu旭ation	 and	 an	 individua旭s	
Limited､	samp旭ing	mode旭s	 ｪLSMｫ	 that	 re旭y	 on	ゲ	 to	ザ	 b旭ood	 samp旭es	
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have	been	primari旭y	used	for	the	estimation	of	area	under	the	curve	
ｪAUCｫ	and	maximum	p旭asma	concentration	ｪCmaxｫsジグpジゲ	The	Bayesian	
approachp	which	 is	based	on	Bayesv	 theoremp	has	been	used	 for	 a	




a	patient	popu旭ations	Coup旭ed	with	patient	 specific	 covariates	 and	
drug	旭eve旭s	in	b旭oodp	the	mode旭s	integrate	popu旭ation	and	individua旭	










mode旭	 is	 to	use	 the	derived	 re旭ationships	between	PK	and	patient	
characteristics	ｪegp	agep	weightp	BMIp	b旭ood	groupｫ	to	predict	PK	in	











same	patient	over	 time	 ｪIOVｫp	outside	of	 the	 therapeutic	windows47 
When	the	therapeutic	window	is	旭argep	PK	variabi旭ity	is	旭ess	important	
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to	attaining	target	activity	旭eve旭s	ｪFigure	ゲp	pane旭	Aｫ	than	when	there	
is	a	narrow	therapeutic	window	ｪFigure	ゲp	pane旭	Bｫs	Indeedp	when	PK	

































葦sザ科|科Limitations to PopPK individua旭 profi旭ing




of	persons	with	hemophi旭ia	undergoing	surgerys17 Since the model 




inhibitorsp	 the	obesep	 and	chi旭drens	Regard旭ess	of	 the	 scenariop	we	
do	not	yet	know	how	many	patients	are	sufficient	to	bui旭d	a	predic､
tive	 brand､	specific	 PopPK	mode旭	 best	 suited	 for	Bayesian	 estima､
tions	Large	data	co旭旭ectionsp	such	as	the	Web､	Accessib旭e	Popu旭ation	
Pharmacokinetics	 Service･Hemophi旭ia	 ｪWAPPS､	Hemoｫp48 aim to 
gather	 FVIII	 and	 FIX	 data	 from	 thousands	 of	 patients	 on	 various	
brands	in	order	to	deve旭op	PopPK	mode旭s	that	span	the	entirety	of	




Given	 dense旭y	 samp旭ed	 profi旭esp	 traditiona旭	 noncompartmenta旭	
ana旭ysis	 produces	 PK	 estimates	 equiva旭ent	 to	 PopPK	 estimatessジゾ 
Bayesian	forecasting	of	individua旭	PK	having	a	set	of	旭imited	patient	
activity	旭eve旭s	has	an	uncertainty	that	is	tied	to	the	number	and	tim､










b旭eedingｫp	 where	 PD	 p旭ays	 a	 more	 important	 ro旭es	 For	 examp旭ep	
p旭asma	 FIX	 activity	 旭eve旭s	may	 represent	 a	 suboptima旭	marker	 for	




旭eve旭p	 presumab旭y	 affecting	 their	 extravascu旭ar	 distributionp	 which	
trans旭ates	into	differing	PK	characteristics	as	we旭旭	as	differences	in	









to	 PK､	tai旭ored	 dosings52	 This	 was	 not	 without	 hesitation	 where	
dai旭y	 dosing	 was	 a	 barrier	 un旭ess	 b旭eeding	 frequency	 was	 great旭y	
reduceds	 It	was	 interesting	 to	note	 that	 number	of	 b旭ood	 samp旭es	
and	 frequency	of	 samp旭ing	 for	PK	estimation	were	not	barriers	 to	
acceptance52	suggesting	that	fo旭旭ow､	up	samp旭es	for	verification	of	a	
new	regimen	wou旭d	be	feasib旭es	Whi旭e	resource	rich	countries	using	
high	 dose	 prophy旭axis	 ｪゴグ､	ジグ	IU｠kg	Qジ芦	hｫ	may	 use	 a	 PK､	tai旭ored	
approach	to	reduce	costsp	resource	poorer	countries	using	旭ow	dose	
prophy旭axis	ｪ葦､	ゲグ	IU｠kg	twice	week旭yｫ	may	use	PK､	tai旭oring	to	opti､
mize	 their	 旭imited	 resources	 ｪegp	 guide	 administration	 around	high	
risk	activitiesｫs
Fina旭旭yp	a	practica旭	 旭imitation	to	the	adoption	of	a	PopPK	based	
tai旭oring	 approach	 is	 the	 comp旭exity	 of	 performing	 a	 post､	hoc	
Bayesian	estimations	 Indeedp	 this	 is	beyond	what	most	hemophi旭ia	
treatment	 centers	 may	 accomp旭ish	 and	 was	 the	 main	 driver	 for	
deve旭oping	WAPPS､	Hemos	 It	 is	 worth	 noting	 thatp	 whereas	 other	
generic	 PopPK	 software	 ｪegp	 Doseme	 LLCp	 Taringa	Q旭dp	 Austra旭iap	
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dosemescomsauq	InsightRXp	Incs	San	Franciscop	CAp	USAp	insight､	rxs
comq	 TDMxp	 University	 of	 Hamburgp	 Hamburgp	 Germanyp	 wwws
tdmxseuｫ	and	specia旭ized	dedicated	software	c旭assified	as	a	medica旭	
device	ｪegp	my	PKFitp	Shire	Pharmaceutica旭	Ho旭dings	Ire旭and	Limitedp	







































ゼ科 |科PK AND POPPK CONTRIBUTION 
TO CHOOSING A SPECIFIC 
FACTOR CONCENTRATE
We	 have	 demonstrated	 that	 know旭edge	 of	 onevs	 PK	 profi旭e	 is	
needed	 to	 optimize	 an	 individua旭	 dosing	 regimens	 But	 is	 there	















to	 make	 sure	 the	 tested	 popu旭ations	 and	 the	 study	 designs	 are	
comparab旭e	and	 robust	enoughs	The	most	efficient	 study	design	
to	ensure	comparabi旭ity	 is	 the	crossover	 studyp	where	each	 indi､
vidua旭	 receives	each	concentrate	and	 they	 therefore	act	as	 their	
own control.ザゾ	Of	 critica旭	 importance	 is	 comparing	on旭y	PK	data	
generated	with	 comparab旭e	methodsr	 too	 oftenp	 and	 sometimes	
even	 in	 crossover	 studiesp	 different	 assumptions	 and	 methods	
ｪinc旭uding	samp旭ing	schedu旭esｫ	are	used	for	the	two	concentrates	
under	comparisonp	and	the	method	more	than	the	concentrates	is	
responsib旭e	 for	 the	observed	differences5861	 Irrespective	of	 the	
goodness	of	the	decision､	making	process	and	qua旭ity	of	the	sup､
portive	evidencep	generic	 choices	at	 the	popu旭ation	 旭eve旭	 cannot	
substitute	 for	 individua旭	PK	profi旭ingp	as	 they	do	not	account	 for	
inter､	patient	variabi旭itys
芦科 |科PARTICIPATING IN LARGE PRAGMATIC 
POPPK DATA COLLECTIONS
Unti旭	 recent旭yp	 the	 vast	 majority	 of	 PK	 and	 PopPK	 studies	 have	
been	 performed	 by	 drug	manufacturers	 to	 support	 the	 fi旭ing	 of	
regu旭atory	 app旭ications	 or	 by	 a	 few	 specia旭ized	 research	 centers	
keen	in	using	PK	to	tai旭or	treatments葦pゲグpズグpズジp葦ゴ	These	studies	have	
a旭so	been	comp旭eted	to	contro旭	or	compare	cost	of	different	con､
centrates	 or	 regimens6365	 and	 to	 deve旭op	 new	 PK	 app旭ications	
to	hemophi旭ias葦pズグ	PK	 is	now	becoming	more	often	considered	 in	
decision	 making	 in	 hemophi旭ias	 This	 has	 been	 precipitated	 by	 a	
higher	 usage	 and	 capabi旭ity	 of	web､	based	 app旭icationsp	more	 in､
tense	internationa旭	research	co旭旭aborationp	 旭arger	number	of	con､
centrates	competing	on	the	marketp	 the	advent	of	EHL	products	
and	 the	 continuous	 pressure	 on	 fair	 use	 of	 resourcesp	 inc旭uding	
tendering	processess	In	this	era	of	旭arge	web､	based	databases	used	
to	 support	 day､	to､	day	 management	 of	 hemophi旭ia	 inc旭uding	 the	
UKHCDO	database	ｪwwwsukhcdosorgｫp	the	American	Thrombosis	
ｹ	 Hemostasis	 Network	 ｪATHNｫ	 ｪwwwsathnsorgｫp	 the	 Austra旭ian､	
Canadian	B旭eeding	Disorders	Registry	ｪABDR	ｬwwwsb旭oodsgovsau｠
abdrｭ｠CBDR	 ｬwwwscbdrscaｭｫ	 fami旭y	 of	 productsp	 the	 FranceCoag	
database	 ｪwwwsfrancecoagsorgｫp	 and	 the	 new旭y	 旭aunched	Wor旭d	















Time to 0.05 IU/mL = 58 h (51, 65) 
Time to 0.03 IU/mL = 83 h (73, 94)
Time to 0.01 IU/mL = 109 h (95, 123)
Half-life = 16 h (13.5, 18.5)
Panel (A)







Dose = 2500 IU
Interval = 72 h
Trough = 0.03 IU/mL
Time below 0.05 IU/mL per infusion = 13 h
Weekly dose = 5833 IU
Panel (B)















Dose = 4000 IU
Interval = 72 h
Trough = 0.047 IU/mL
Time below 0.05 IU/mL per infusion = 2 h
Weekly dose = 9333 IU
Panel (C)





Time below 0.05 IU/mL per infusion = none
Weekly dose = 4900 IU
Dose = 1400 IU
Interval = 48 h
Trough = 0.05 IU/mL
Panel (D)




























科架 科 | 科ズジザIORIO ET AL.
Federation	 of	 Haemophi旭ia	 ｪWFHｫ	 Patient	 Registry	 ｪwwwswfhs
org｠en｠wbdrｫ	there	is	an	opportunity	to	perform	旭arge	popu旭ation	









Domain Cueing question Characteristic assessed Notes




































Intervention Did the administration of the concentrates under assessment happen in a simi旭ar way across the comparators and with 
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database	 and	 has	 been	 integrated	 into	 the	 hemophi旭ia	 manage､
ment	software	used	 in	 the	Czech	Repub旭icp	 the	USp	and	Canadas	
One	of	the	important	advancements	provided	by	these	旭arge	data	
co旭旭ections	 invo旭ves	 the	 simu旭taneous	 consideration	 of	 c旭inica旭	
informationp	 such	 as	 b旭eeding	 and	 treatment	 旭ogsp	 adherence	 in､
formationp	 and	 activity	 旭eve旭ss	 It	 is	 important	 for	 re旭iab旭e	 PK	 in､
formation	to	be	storedp	centra旭izedp	and	ana旭yzed	to	enhance	our	
co旭旭ective	 capacity	 to	 understand	 how	 to	 best	 individua旭ize	 and	











with	dose	 tai旭oring	 and	 this	 can	be	 achieved	 through	 a	number	of	
methodss	PopPK	methods	that	integrate	information	from	the	pop､
u旭ation	 of	 persons	with	 hemophi旭ia	 a旭ong	with	 individua旭	 PK	 infor､
mation	and	characteristics	are	poised	 to	provide	a	convenient	and	
accessib旭e	means	 of	 individua旭izing	 dose	 tai旭oringq	 especia旭旭y	when	
made	 avai旭ab旭e	 to	 treaters	 and	 patients	 through	 dedicated	 soft､
warep	a旭beit	 raising	further	questions	about	appropriate	thresho旭ds	
for	troughs	and｠or	peaks	for	participation	in	activities	with	varying	




The	 authors	 wou旭d	 旭ike	 to	 acknow旭edge	 the	 contribution	 of	
the	 fo旭旭owing	 externa旭	 experts	 who	 provided	 comments	 on	
Domain Cueing question Characteristic assessed Notes
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G LOSSARY OF TERMS
Area under the curve ｪAUCｫr	Surface	beneath	 the	activity	vs	 time	
profi旭eq	it	measures	wexposurex	to	the	concentrates
Baseline factor levelr	 The	 旭eve旭	 of	 factor	 activity	measured	 in	















Ha旭f､旭ifer	 Time	 required	 for	 the	p旭asma	activity	 to	decrease	by	





Internationa旭 Units ｪIUｫr	The	unit	used	 to	define	p旭asma	 factor	
activity	旭eve旭s	The	norma旭	range	for	factor	VIII	and	factor	IX	is	from	
グsズ	IU｠mL	ｪズグ	IU｠dLｫ	to	ゲsズ	IU｠mL	ｪゲズグ	IU｠dLｫs
Immune to旭erance induction treatment ｪITIｫr	Administration	of	
factor	VIII	or	IX	meant	to	induce	to旭erance	in	patients	with	inhibitory	
antibodiess
Inter､individua旭 variabi旭ity ｪIIVｫr	 The	 variabi旭ity	 of	 PK	between	
different	individua旭s
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Inter､occasion variabi旭ity ｪIOVｫr	The	variabi旭ity	of	PK	over	time	
within	the	same	individua旭
Lean body weightr	 Residua旭	 body	 weight	 after	 subtraction	 of	
the	fat	component	 ｪequa旭	or	more	often	 inferior	 to	the	tota旭	body	
weightｫ
Maximum p旭asma concentration ｪCmaxｫr	 The	 p旭asma	 factor	 ac､
tivity	measured	after	a	concentrate	 infusions	For	bo旭us	 infusions	 it	
shou旭d	 theoretica旭旭y	 be	 the	 concentration	measured	 at	 the	 end	of	
the	infusion	ｪC0ｫs



















two	 infusions	 ｪusua旭旭y	reached	 immediate旭y	before	the	subsequent	
infusionp	and	a旭so	ca旭旭ed	pre､	dose	旭eve旭ｫs
Vo旭ume of distributionr	 The	 theoretica旭	 vo旭ume	 that	wou旭d	 be	
necessary	 to	 contain	 the	 tota旭	 amount	 of	 a	 factor	 concentrate	 to	
generate	 the	 same	activity	 旭eve旭	 that	 it	 is	observed	 in	 the	p旭asmas	
The	旭ink	between	the	tota旭	amount	of	factor	concentrate	in	the	body	
and	the	p旭asma	activitys

























for	 persona旭ized	 treatment	 in	 haemophi旭iar	 a	 De旭phi	 consensus	
statements	Haemophi旭ias	ゴグゲゼqゴザreゲゼグ･ゾs
	 ジs	 Ljung	 Rp	 Fischer	 Kp	 Carcao	 Mp	 et	 a旭s	 Practica旭	 considerations	 in	
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ANs	 Mode旭ing	 of	 body	 weight	 metrics	 for	 effective	 and	 cost､	
efficient	 conventiona旭	 factor	VIII	 dosing	 in	 hemophi旭ia	A	 prophy､
旭axiss	Pharmaceuticss	ゴグゲゼqゾrEジゼs
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